Mylan Beats Sanofi On Lantus Patent

Company Ready To Launch Insulin Glargine Upon FDA Approval

Lantus
A Lantus SoloStar device patent has been found not infringed and invalid for lack of written description • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin